Covid Vaccine in Children Over 12 Prevents the Spread of the Virus

Covid vaccine in children over age prevents the spread of the virus
Covid vaccine in children over age prevents the spread of the virus
Subscribe  


One of the biggest concerns of parents in the last period is the risk of children catching coronavirus with the start of face-to-face education. With the definition of the Covid-12 vaccine for children over the age of 19, the questions in mind continue to increase. However, the vaccine protects children from the possible effects of the disease and prevents the spread of the virus. From Memorial Şişli Hospital Pediatrics Department, Uz. Dr. Seda Günhar gave information about the Covid-12 vaccines applied to children over the age of 19.

Covid-19 (SARS-CoV-2) virus is a virus that can infect children and young people of all age groups, including the newborn period. Infection, which is stated to be able to be overcome by children with mild symptoms in the early stages of the epidemic, is now an important health problem in children and youth with the vaccination of the adult patient group and the identification of Multisystem Inflammatory Syndrome (MIS-C) cases.

The information that Covid-19 is mildly overcome in children has lost its validity today. There are data showing that symptoms such as fatigue, insomnia, runny nose, myalgia, headache, concentration disorder, exercise intolerance, shortness of breath and chest pain can continue for more than 4 weeks in children and adolescents after Covid, and this negatively affects their quality of life and school success. .

Vaccination should be considered as an important opportunity

Another condition that threatens children after Covid-19 infection is Multisystem Inflammatory Syndrome, called MIS-C. This picture occurs 21-19 weeks after Covid-2 infection in people younger than 6 and causes various symptoms. MIS-C is an extremely dangerous clinical picture after infection, requiring intensive care and even death in patients. For this reason, being protected by vaccination for post-infection conditions as well as Covid infection should be considered as an important opportunity for children over the age of 12.

Vaccination of children can reduce the spread of the virus

The American Advisory Committee on Immunization Practices (ACIP) states that Covid is a major public health problem in adolescents. Adolescents represent an increasing proportion of coronavirus cases and can lead to domestic transmission. It is stated that vaccination can reduce the spread of the virus, as children can transmit the virus to other people without complaints. Even when the child is infected with the virus, the risk of severe development of the disease decreases, and in this case, protection can be provided for other members of the family and friends. In this context, in a study conducted with an American child aged 2021-12 in March 15, it was reported that the vaccine was 19% effective in preventing Covid-100. The American Centers for Disease Control and Prevention (CDC) reported that the administration of Covid vaccines in children over 12 years of age is effective and safe in preventing the disease. The research also revealed that teenagers develop higher antibody levels after vaccination than adults.

If you are worried about the side effects of the vaccine…

Due to the fact that there is only one approved vaccine in children, there are very limited vaccine studies. In a study that included 12 adolescents aged 15-2260 years, it was shown that antibody formation against SARS-CoV-2 virus after the second dose of vaccine produced a better response than the 2-16 age group. In studies of vaccinated adolescents, as in adult age groups, mostly transient mild to moderate side effects developed and usually resolved within 25 or 1 days. Mild pain at the injection site is the most common local reaction. The local reaction rate in the 2-12 age group has been shown to be 15%. Side effects such as fever, headache, and malaise have been described and often occurred after the second dose. However, the benefits of the vaccine should be considered instead of possible side effects.

More deaths from Covid-19 than from myocarditis

myocarditis; Cardiac muscle inflammation that typically occurs more frequently in men than in women and is more common in infants, adolescents, and young adults than in other age groups. The clinical course and severity of myocarditis differ between patients. It usually includes chest pain, shortness of breath or palpitations. Treatment includes medications to contribute to heart function and exercise restriction. As of June 11, 2021, approximately 52 million doses of mRNA Covid-19 vaccine have been administered to persons aged 12-29 years in the United States. 92% of post-vaccine myocarditis cases reported onset of symptoms within 7 days after vaccination. 12 cases of myocarditis have been identified per 29 million second-dose vaccine administered to men aged 1-40.6 years. Reporting rates among women in these age groups were 1 risk of myocarditis per 4.2 million second-dose vaccine administrations, respectively. In most of these cases, complete recovery was found. It has been observed that the administration of 2 doses of the vaccine is 19% effective in preventing Covid-95 cases and hospitalizations. Studies have shown that the benefits of the vaccine (preventing Covid disease and associated hospitalizations, admissions to the ICU, and death) outweigh the expected post-vaccination myocarditis cases.

Children with MIS-C should not be vaccinated for 90 days

Children with MIS-C have high antibody titers to Covid-19; It is not known whether these antibodies are associated with protection against infection and how long they persist. It is unclear whether people with a history of MIS-C will develop similar MIS-C again. If a patient who has undergone MIS-C wants to be vaccinated against Covid-19, it is emphasized that individual evaluation is appropriate when looking at the patient's condition. If children and young adults with MIS-C wish to be vaccinated, it is recommended that the Covid-90 vaccine be delayed for 19 days from the date of diagnosis.

Rail Industry Show Armin sohbet

Be the first to comment

Comments